Adaptive Biotechnologies Reports Strong Q1 Results, Raises Full-Year MRD Revenue Guidance

summarizeSummary

Adaptive Biotechnologies reported strong first-quarter 2026 financial results, with total revenue increasing 35% year-over-year and a significant improvement in profitability, leading to a raised full-year MRD revenue guidance.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Total revenue increased 35% year-over-year to $70.9 million for the quarter ended March 31, 2026.

• Significant MRD Business Growth

  The Minimal Residual Disease (MRD) business, which contributed 95% of total revenue, grew 53% year-over-year to $67.1 million, driven by a 41% increase in clonoSEQ test volume.

• Improved Profitability Metrics

  Net loss decreased to $20.0 million from $29.8 million in Q1 2025, and Adjusted EBITDA loss significantly narrowed to $2.5 million from $12.7 million in the prior year period.

• Raised Full-Year Revenue Guidance

  The company raised its full-year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

auto_awesomeAnalysis

Adaptive Biotechnologies delivered robust first-quarter results, demonstrating strong execution in its core Minimal Residual Disease (MRD) business. The substantial revenue growth, particularly in MRD, coupled with a significant reduction in net loss and Adjusted EBITDA loss, indicates improving operational efficiency and market penetration. The upward revision of full-year MRD revenue guidance signals management's confidence in continued growth and strengthens the company's financial outlook. This performance reinforces Adaptive Biotechnologies' market leadership and its ability to translate its immune medicine platform into commercial success.